Table 1 |
|
|
Baseline patient characteristics (n = 78) |
|
|
Age (years), median (IQR) |
56.4 (48 to 66.75) |
|
|
|
|
Body Mass Index (kg/m2), median (IQR) |
26.6 (24.4 to 30.2) |
|
|
|
|
Female |
61 (78.2%) |
|
|
|
|
Ever Smoked |
47 (60.3%) |
|
|
|
|
Current smokers |
22 (28.2%) |
|
|
|
|
Caucasian race |
73 (93.6%) |
|
|
|
|
*Continuing triple DMARD therapy |
51 (65.4%) |
|
|
|
|
*Continuing methotrexate |
60 (76.9%) |
|
|
|
|
*Continuing sulfasalazine |
60 (76.9%) |
|
|
|
|
*Continuing hydroxychloroquine |
70 (89.7%) |
|
|
|
|
Initiation of leflunomide with loading dose |
7 (9.0%) |
|
|
|
|
Anti-CCP antibody (n = 77) |
38 (49.4%) |
|
|
|
|
Rheumatoid factor |
46 (59.0%) |
|
|
|
|
Shared epitope (n = 76) |
52 (68.4%) |
|
|
|
|
Duration of disease prior to initiation of leflunomide (weeks), median (IQR) |
48 (32.3 to 92.1) |
|
|
|
|
DAS28 (at start of leflunomide therapy), median (IQR) |
5.8 (5.2 to 6.5) |
|
|
|
|
*- Participants could be included in any or all of these groups. |
|
|
Wiese et al. Arthritis Research & Therapy 2012 14:R163 doi:10.1186/ar3911 |
|
